drugset / Trial / NCT03472040

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040

Phase 2/3 Completed 387 enrolled BioCryst Pharmaceuticals
NaSingle-groupOpen-labelPrevention

Summary

This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).

Timeline

Start
2018-02-16
Primary completion
2022-04-27
Completion
2022-04-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject berotralstat Small molecule 110 mg Oral
Subject berotralstat Small molecule 150 mg Oral

Indications